Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06305806 · ClinicalTrials.gov registry record · Phase 2
RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)
A Phase 2 study, sponsored by Kanecia Obie Zimmerman.
- Completed
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
NCT06305806: Completed Phase 2 study, sponsored by Kanecia Obie Zimmerman.
NCT06305806 is a Phase 2 study that has completed, run by Kanecia Obie Zimmerman. The registered enrollment target is 181 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06305806, a Phase 2 study, has completed, sponsored by Kanecia Obie Zimmerman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
Study Summary
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in PASC participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs.
Primary Outcome
The OHQ / OIQ is a measure of orthostatic intolerance and includes a 6-item symptom assessment (OHSA) and the 4-item Daily Activity Scale (OHDAS). Each item is scored from 0 (none/no interference) to 10 (worst possible/complete interference), describing the preceding week. The OHSA composite score is the average of the first 6 non-zero items and the OHDAS composite score is the average of the last 4 non-zero items. The OHQ/OIQ composite score is the average of the OHSA and OHDAS composite scores
Interventions
- BEHAVIORAL Usual Care
- BEHAVIORAL Coordinated Care
- DRUG Ivabradine
- DRUG Ivabradine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2024-03-11 |
| Est. Completion | 2025-12-17 |
| Phase | Phase 2 |
What the finished NCT06305806 record still lists
NCT06305806 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% higher).
The record links to 0 conditions, and to 4 interventions - of which Usual Care is the first listed.
NCT06305806 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06305806 about?
NCT06305806 is a clinical study titled "RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)". This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-ar...
What is the current status of trial NCT06305806?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2024-03-11. Estimated completion is 2025-12-17.
What interventions are being tested in trial NCT06305806?
The interventions under investigation include: Usual Care (BEHAVIORAL), Coordinated Care (BEHAVIORAL), Ivabradine (DRUG), Ivabradine Placebo (DRUG).
Who is sponsoring clinical trial NCT06305806?
This trial is sponsored by Kanecia Obie Zimmerman, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06305806's enrollment target sits among peer trials
181 365th of 2000 higher than 1,636 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI